[ASAP] Endogenous Iron(II) Self-Enriched Fenton Nanocatalyst via FTH1 Activity Inhibition and Iron(III) Reduction for Amplified Cancer Ferroptosis Therapy 🔗 Access full article via ACS Molecular Pharmaceutics Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.4c01292 Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
